跳转至内容
Merck
CN

H-027

Supelco

(±)-11-羟基-Δ9-四氢大麻酚标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C21H30O3
CAS Number:
分子量:
330.46
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

drug control

psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

cannabis testing
forensics and toxicology

包装形式

single component solution

储存温度

2-8°C

SMILES字符串

OC1=CC(CCCCC)=CC2=C1C3C=C(CO)CCC3C(O2)(C)C

InChI

1S/C21H30O3/c1-4-5-6-7-14-11-18(23)20-16-10-15(13-22)8-9-17(16)21(2,3)24-19(20)12-14/h10-12,16-17,22-23H,4-9,13H2,1-3H3

InChI key

YCBKSSAWEUDACY-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

经认证的加标溶液®,适用于LC/MS或GC/MS应用,用于大麻素测试,尿液药物测试,临床毒理学或法医分析。11-羟基-Δ9-THC 是大麻主要精神活性成分(Δ9--四氢大麻酚 (Δ9-THC))的主要氧化代谢物。

应用

该认证加标溶液®适用于通过 HPLC、GC/MS 或 LC-MS/MS 法进行 (±)-11-羟基-Δ9-THC 测定,从而用于法医分析、临床毒理学、尿液药物测试和大麻效力或杂质分析测试等应用。该认证标准物质(CRM)还可作如下用途:
  • 使用超高效液相色谱(UHPLC)结合三重四极杆质谱法在液-液萃取后定量测定人血浆样品中的大麻二酚和 Δ9-四氢大麻酚,以及鉴定少量大麻素
  • 基于液相色谱-串联质谱(LC-MS/MS)法在固相萃取(SPE)后测定口服液样品中的 10 种大麻素
  • 通过气相色谱(GC)联合三重四极杆质谱仪分析血浆和尿液中 Δ9-四氢大麻酚(Δ9-THC)及其三种代谢物
  • 开发基于固相萃取(SPE)的自动样品制备方法,以使用液相色谱-质谱法(LC-MS)测定血清、唾液和尿液中 ∆9--四氢大麻酚(THC)及其三种主要代谢物
  • 通过大气压化学电离气相色谱-串联质谱法(APGC-MS/MS)同时测定人血清样品中的大麻素及其代谢物

特点和优势

  • 完全符合 ISO/IEC 17025 和 ISO 17034 认证
  • 附综合分析证书(CoA),包括稳定性、均匀性、浓度准确性、不确定性和可追溯性数据
  • 通过实时稳定性研究严格测试,以确保准确性和保质期
  • 使用合格的精密天平进行重量准备,以确保最小不确定性
  • 氩气环境下火焰密封,装入安瓿以便长期保存
  • 提供方便的 DEA 豁免格式,以提高实验室效率

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Cynthia Coulter et al.
Journal of analytical toxicology, 32(8), 653-658 (2008-11-15)
An analytical procedure for the determination of Delta9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCA), and 11-hydroxy-Delta9-tetrahydrocannabinol (11-OH-THC) in whole blood has been developed and validated using liquid chromatography with tandem mass spectral detection (MS). Cannabinoids present in the blood samples were quantified using
Erin L Karschner et al.
Analytical and bioanalytical chemistry, 397(2), 603-611 (2010-03-23)
A sensitive analytical method for simultaneous quantification of sub-nanogram concentrations of cannabidiol (CBD), Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) in plasma is presented for monitoring cannabinoid pharmacotherapy and illicit cannabis use. Analytes were extracted from 1 mL plasma by
Erin L Karschner et al.
Clinical chemistry, 57(1), 66-75 (2010-11-17)
Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications
Gisela Skopp et al.
Archiv fur Kriminologie, 229(5-6), 154-162 (2012-07-28)
The exculpatory statement that a positive THC finding in the blood is due to the consumption of hemp products or passive exposure to cannabis smoke has been disproved by the monitoring of hemp products and recent passive inhalation studies conducted
David A Gorelick et al.
Journal of clinical psychopharmacology, 31(5), 603-612 (2011-08-27)
Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ⁹-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持